Intratumoral therapies and in-situ vaccination for melanoma.
Hum Vaccin Immunother
; 18(3): 1890512, 2022 05 31.
Article
en En
| MEDLINE
| ID: mdl-35559766
ABSTRACT
Skin cancers are among the most physically accessible malignancies, so local delivery of a medication into the tumor, so-called intratumoral therapy, is an appealing route of drug administration. Intratumoral therapies have the potential to increase local drug concentration and/or attract immune cells to the local tumor microenvironment, possibly with fewer systemic side effects. A wide array of intratumoral agents have been studied to date in patients with advanced melanoma, including chemotherapeutic drugs, immune modulating agents, and cancer-directed vaccines. In this review, we will summarize the key pre-clinical and clinical data supporting the use of intratumoral therapy for advanced unresectable and metastatic melanoma. First, we will discuss the history of intratumoral immunotherapy for the treatment of melanoma and the various agents studied to date. Second, we will explore how intratumoral therapies can constitute an in situ vaccine, potentially leading to disease control both locally and systemically. Finally, we will highlight opportunities in the field and key future directions.
Palabras clave
Texto completo:
1
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Vacunas contra el Cáncer
/
Melanoma
Límite:
Humans
Idioma:
En
Revista:
Hum Vaccin Immunother
Año:
2022
Tipo del documento:
Article
País de afiliación:
Estados Unidos